Techniclone Shares Up 14% on Licensing Deal
- Share via
Bloomberg News
Techniclone Corp.’s stock on Monday rose 14%, or 34 cents a share, to $2.75 in Nasdaq trading after the Tustin biopharmaceutical company said it agreed to license part of its tumor-treatment technology to Germany’s Merck KgaA.
Volume surpassed 2.6 million shares, more than triple the average daily volume over the last three months.
Merck KgaA will pay an undisclosed amount up front and royalties on any sales.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
